Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2005 Mar;64(Suppl 2):ii87–ii90. doi: 10.1136/ard.2004.032276

Psoriasis treatment: current and emerging directed therapies

L Winterfield, A Menter, K Gordon, A Gottlieb
PMCID: PMC1766866  PMID: 15708946

Abstract

Quality of life studies in patients with cutaneous psoriasis attest to its significant impact on day to day activities and personal social interactions. Up to 40% of patients with psoriasis may develop psoriatic arthritis, usually within 5–10 years after onset of the cutaneous disease, heightening quality of life issues. These data have prompted an increased awareness and interest in more aggressive management of psoriasis; coupled with a better understanding of immunopathogenesis, this has led to the development of new agents targeting specific cells and molecules involved in the development and maintenance of psoriatic plaques. Although non-biological therapies, including methotrexate and ciclosporin, show significant efficacy their side effect profiles have precluded their long term use for moderate to severe psoriasis. This review concentrates on new biological agents, focusing on the three agents approved for psoriasis within the past 18 months (alefacept, efalizumab, and etanercept). Phase II and III trial data on other agents in development (adalimumab and infliximab) are also presented. Surveys show many patients want to be treated more aggressively. It is hoped that the introduction of new agents that are more targeted and that hold the promise of fewer side effects will cause patients and their physicians to reconsider systemic treatment and, as a consequence, stimulate other patients to reconsider treatment for psoriasis. Close cooperation between dermatologists and rheumatologists, particularly in the area of psoriatic joint disease, will enhance these considerations.

Full Text

The Full Text of this article is available as a PDF (68.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ashcroft D. M., Li Wan Po A., Williams H. C., Griffiths C. E. Combination regimens of topical calcipotriene in chronic plaque psoriasis: systematic review of efficacy and tolerability. Arch Dermatol. 2000 Dec;136(12):1536–1543. doi: 10.1001/archderm.136.12.1536. [DOI] [PubMed] [Google Scholar]
  2. Ashcroft D. M., Li Wan Po A., Williams H. C., Griffiths C. E. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther. 1998 Oct;23(5):391–398. doi: 10.1046/j.1365-2710.1998.00181.x. [DOI] [PubMed] [Google Scholar]
  3. Bagel J., Garland W. T., Breneman D., Holick M., Littlejohn T. W., Crosby D., Faust H., Fivenson D., Nichols J. Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial. J Am Acad Dermatol. 1998 Jun;38(6 Pt 1):938–944. doi: 10.1016/s0190-9622(98)70590-0. [DOI] [PubMed] [Google Scholar]
  4. Bjerke J. R., Krogh H. K., Matre R. Characterization of mononuclear cell infiltrates in psoriatic lesions. J Invest Dermatol. 1978 Nov;71(5):340–343. doi: 10.1111/1523-1747.ep12529841. [DOI] [PubMed] [Google Scholar]
  5. Boehncke W. H., Dressel D., Zollner T. M., Kaufmann R. Pulling the trigger on psoriasis. Nature. 1996 Feb 29;379(6568):777–777. doi: 10.1038/379777a0. [DOI] [PubMed] [Google Scholar]
  6. Bos J. D., Hulsebosch H. J., Krieg S. R., Bakker P. M., Cormane R. H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies. Arch Dermatol Res. 1983;275(3):181–189. doi: 10.1007/BF00510050. [DOI] [PubMed] [Google Scholar]
  7. Chisholm P. L., Williams C. A., Jones W. E., Majeau G. R., Oleson F. B., Burrus-Fischer B., Meier W., Hochman P. S. The effects of an immunomodulatory LFA3-IgG1 fusion protein on nonhuman primates. Ther Immunol. 1994 Aug;1(4):205–216. [PubMed] [Google Scholar]
  8. Christophers E. Psoriasis--epidemiology and clinical spectrum. Clin Exp Dermatol. 2001 Jun;26(4):314–320. doi: 10.1046/j.1365-2230.2001.00832.x. [DOI] [PubMed] [Google Scholar]
  9. Duthie M. S., Kimber I., Norval M. The effects of ultraviolet radiation on the human immune system. Br J Dermatol. 1999 Jun;140(6):995–1009. doi: 10.1046/j.1365-2133.1999.02898.x. [DOI] [PubMed] [Google Scholar]
  10. Ellis C. N., Gorsulowsky D. C., Hamilton T. A., Billings J. K., Brown M. D., Headington J. T., Cooper K. D., Baadsgaard O., Duell E. A., Annesley T. M. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986 Dec 12;256(22):3110–3116. [PubMed] [Google Scholar]
  11. Finlay A. Y., Kelly S. E. Psoriasis--an index of disability. Clin Exp Dermatol. 1987 Jan;12(1):8–11. doi: 10.1111/j.1365-2230.1987.tb01844.x. [DOI] [PubMed] [Google Scholar]
  12. Finlay A. Y. Quality of life assessments in dermatology. Semin Cutan Med Surg. 1998 Dec;17(4):291–296. doi: 10.1016/s1085-5629(98)80026-6. [DOI] [PubMed] [Google Scholar]
  13. Fleischer A. B., Jr, Feldman S. R., Rapp S. R., Reboussin D. M., Exum M. L., Clark A. R., Rajashekhar V. Disease severity measures in a population of psoriasis patients: the symptoms of psoriasis correlate with self-administered psoriasis area severity index scores. J Invest Dermatol. 1996 Jul;107(1):26–29. doi: 10.1111/1523-1747.ep12297659. [DOI] [PubMed] [Google Scholar]
  14. Freeman Amy Krupnick, Linowski Gregory J., Brady Christopher, Lind Leah, Vanveldhuisen Paul, Singer Giselle, Lebwohl Mark. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003 Apr;48(4):564–568. doi: 10.1067/mjd.2003.169. [DOI] [PubMed] [Google Scholar]
  15. Gaylor Minh-Ly N., Duvic Madeleine. Generalized pustular psoriasis following withdrawal of efalizumab. J Drugs Dermatol. 2004 Jan-Feb;3(1):77–79. [PubMed] [Google Scholar]
  16. Gilhar A., David M., Ullmann Y., Berkutski T., Kalish R. S. T-lymphocyte dependence of psoriatic pathology in human psoriatic skin grafted to SCID mice. J Invest Dermatol. 1997 Sep;109(3):283–288. doi: 10.1111/1523-1747.ep12335758. [DOI] [PubMed] [Google Scholar]
  17. Gordon Kenneth B., Papp Kim A., Hamilton Tiffani K., Walicke Patricia A., Dummer Wolfgang, Li Nicole, Bresnahan Brian W., Menter Alan, Efalizumab Study Group Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17;290(23):3073–3080. doi: 10.1001/jama.290.23.3073. [DOI] [PubMed] [Google Scholar]
  18. Gottlieb Alice B., Matheson Robert T., Lowe Nicholas, Krueger Gerald G., Kang Sewon, Goffe Bernard S., Gaspari Anthony A., Ling Mark, Weinstein Gerald D., Nayak Anjuli. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol. 2003 Dec;139(12):1627–1632. doi: 10.1001/archderm.139.12.1627. [DOI] [PubMed] [Google Scholar]
  19. Gottlieb S. L., Gilleaudeau P., Johnson R., Estes L., Woodworth T. G., Gottlieb A. B., Krueger J. G. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995 May;1(5):442–447. doi: 10.1038/nm0595-442. [DOI] [PubMed] [Google Scholar]
  20. Gupta A. K., Grober J. S., Hamilton T. A., Ellis C. N., Siegel M. T., Voorhees J. J., McCune W. J. Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. J Rheumatol. 1995 May;22(5):894–898. [PubMed] [Google Scholar]
  21. Iest J., Boer J. Combined treatment of psoriasis with acitretin and UVB phototherapy compared with acitretin alone and UVB alone. Br J Dermatol. 1989 May;120(5):665–670. doi: 10.1111/j.1365-2133.1989.tb01354.x. [DOI] [PubMed] [Google Scholar]
  22. Jones E. L., Epinette W. W., Hackney V. C., Menendez L., Frost P. Treatment of psoriasis with oral mycophenolic acid. J Invest Dermatol. 1975 Dec;65(6):537–542. doi: 10.1111/1523-1747.ep12610346. [DOI] [PubMed] [Google Scholar]
  23. Kraan Maarten C., van Kuijk Arno W. R., Dinant Huibert J., Goedkoop Amber Y., Smeets Tom J. M., de Rie Menno A., Dijkmans Ben A. C., Vaishnaw Akshay K., Bos Jan D., Tak Paul P. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum. 2002 Oct;46(10):2776–2784. doi: 10.1002/art.10543. [DOI] [PubMed] [Google Scholar]
  24. Krueger G. G., Feldman S. R., Camisa C., Duvic M., Elder J. T., Gottlieb A. B., Koo J., Krueger J. G., Lebwohl M., Lowe N. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):281–285. doi: 10.1067/mjd.2000.106374. [DOI] [PubMed] [Google Scholar]
  25. Krueger J. G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii30–ii36. doi: 10.1136/ard.2004.031120. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Krueger J, Gottlieb A, Miller B, Dedrick R, Garovoy M, Walicke P. Anti-CD11a treatment for psoriasis concurrently increases circulating T-cells and decreases plaque T-cells, consistent with inhibition of cutaneous T-cell trafficking. J Invest Dermatol. 2000 Aug;115(2):333–333. doi: 10.1046/j.1523-1747.2000.00abs-8.x. [DOI] [PubMed] [Google Scholar]
  27. Leavell U. W., Jr, Yarbro J. W. Hydroxyurea. A new treatment for psoriasis. Arch Dermatol. 1970 Aug;102(2):144–150. doi: 10.1001/archderm.102.2.144. [DOI] [PubMed] [Google Scholar]
  28. Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol. 1999 Sep;41(3 Pt 2):S22–S24. doi: 10.1016/s0190-9622(99)70362-2. [DOI] [PubMed] [Google Scholar]
  29. Lebwohl M., Drake L., Menter A., Koo J., Gottlieb A. B., Zanolli M., Young M., McClelland P. Consensus conference: acitretin in combination with UVB or PUVA in the treatment of psoriasis. J Am Acad Dermatol. 2001 Oct;45(4):544–553. doi: 10.1067/mjd.2001.116347. [DOI] [PubMed] [Google Scholar]
  30. Lebwohl M., Ting P. T., Koo J. Y. M. Psoriasis treatment: traditional therapy. Ann Rheum Dis. 2005 Mar;64 (Suppl 2):ii83–ii86. doi: 10.1136/ard.2004.030791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Lebwohl Mark, Christophers Enno, Langley Richard, Ortonne Jean P., Roberts Janet, Griffiths Christopher E. M., Alefacept Clinical Study Group An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol. 2003 Jun;139(6):719–727. doi: 10.1001/archderm.139.6.719. [DOI] [PubMed] [Google Scholar]
  32. Leonardi Craig L., Powers Jerold L., Matheson Robert T., Goffe Bernard S., Zitnik Ralph, Wang Andrea, Gottlieb Alice B., Etanercept Psoriasis Study Group Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003 Nov 20;349(21):2014–2022. doi: 10.1056/NEJMoa030409. [DOI] [PubMed] [Google Scholar]
  33. Ling M. R. Acitretin: optimal dosing strategies. J Am Acad Dermatol. 1999 Sep;41(3 Pt 2):S13–S17. doi: 10.1016/s0190-9622(99)70360-9. [DOI] [PubMed] [Google Scholar]
  34. Lowe N. J., Lazarus V., Matt L. Systemic retinoid therapy for psoriasis. J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):186–191. doi: 10.1016/s0190-9622(88)70163-2. [DOI] [PubMed] [Google Scholar]
  35. Lowe N. J., Prystowsky J. H., Bourget T., Edelstein J., Nychay S., Armstrong R. Acitretin plus UVB therapy for psoriasis. Comparisons with placebo plus UVB and acitretin alone. J Am Acad Dermatol. 1991 Apr;24(4):591–594. doi: 10.1016/0190-9622(91)70089-k. [DOI] [PubMed] [Google Scholar]
  36. Majeau G. R., Meier W., Jimmo B., Kioussis D., Hochman P. S. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol. 1994 Mar 15;152(6):2753–2767. [PubMed] [Google Scholar]
  37. Mckenna K. E., Stern R. S. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol. 1996 Mar;34(3):534–538. doi: 10.1016/s0190-9622(96)90469-7. [DOI] [PubMed] [Google Scholar]
  38. Mease P. J., Goffe B. S., Metz J., VanderStoep A., Finck B., Burge D. J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet. 2000 Jul 29;356(9227):385–390. doi: 10.1016/S0140-6736(00)02530-7. [DOI] [PubMed] [Google Scholar]
  39. Meier W., Gill A., Rogge M., Dabora R., Majeau G. R., Oleson F. B., Jones W. E., Frazier D., Miatkowski K., Hochman P. S. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol. 1995 Jun;2(3):159–171. [PubMed] [Google Scholar]
  40. Menter M. A., See J. A., Amend W. J., Ellis C. N., Krueger G. G., Lebwohl M., Morison W. L., Prystowsky J. H., Roenigk H. H., Jr, Shupack J. L. Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994. J Am Acad Dermatol. 1996 Feb;34(2 Pt 1):315–321. doi: 10.1016/s0190-9622(96)80148-4. [DOI] [PubMed] [Google Scholar]
  41. Miller G. T., Hochman P. S., Meier W., Tizard R., Bixler S. A., Rosa M. D., Wallner B. P. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med. 1993 Jul 1;178(1):211–222. doi: 10.1084/jem.178.1.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Morison W. L., Momtaz K., Parrish J. A., Fitzpatrick T. B. Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982 Jan;6(1):46–51. doi: 10.1016/s0190-9622(82)70005-2. [DOI] [PubMed] [Google Scholar]
  43. Mrowietz Ulrich, Wustlich Stefan, Hoexter Godehart, Graeber Michael, Bräutigam Matthias, Luger Thomas. An experimental ointment formulation of pimecrolimus is effective in psoriasis without occlusion. Acta Derm Venereol. 2003;83(5):351–353. doi: 10.1080/00015550310003791. [DOI] [PubMed] [Google Scholar]
  44. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979 Sep 6;301(10):555–555. doi: 10.1056/NEJM197909063011016. [DOI] [PubMed] [Google Scholar]
  45. Nickoloff B. J., Kunkel S. L., Burdick M., Strieter R. M. Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol. 1995 Mar;146(3):580–588. [PMC free article] [PubMed] [Google Scholar]
  46. Ohta Y., Hamada Y., Katsuoka K. Expression of IL-18 in psoriasis. Arch Dermatol Res. 2001 Jul;293(7):334–342. doi: 10.1007/s004030100240. [DOI] [PubMed] [Google Scholar]
  47. Paul B. S., Momtaz K., Stern R. S., Arndt K. A., Parrish J. A. Combined methotrexate--ultraviolet B therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982 Dec;7(6):758–762. doi: 10.1016/s0190-9622(82)70157-4. [DOI] [PubMed] [Google Scholar]
  48. Rapp S. R., Feldman S. R., Exum M. L., Fleischer A. B., Jr, Reboussin D. M. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x. [DOI] [PubMed] [Google Scholar]
  49. Scerri L. Azathioprine in dermatological practice. An overview with special emphasis on its use in non-bullous inflammatory dermatoses. Adv Exp Med Biol. 1999;455:343–348. [PubMed] [Google Scholar]
  50. Schlaak J. F., Buslau M., Jochum W., Hermann E., Girndt M., Gallati H., Meyer zum Büschenfelde K. H., Fleischer B. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994 Feb;102(2):145–149. doi: 10.1111/1523-1747.ep12371752. [DOI] [PubMed] [Google Scholar]
  51. Singri Prashant, West Dennis P., Gordon Kenneth B. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol. 2002 May;138(5):657–663. doi: 10.1001/archderm.138.5.657. [DOI] [PubMed] [Google Scholar]
  52. Sugai J., Iizuka M., Kawakubo Y., Ozawa A., Ohkido M., Ueyama Y., Tamaoki N., Inokuchi S., Shimamura K. Histological and immunocytochemical studies of human psoriatic lesions transplanted onto SCID mice. J Dermatol Sci. 1998 Jun;17(2):85–92. doi: 10.1016/s0923-1811(97)00077-7. [DOI] [PubMed] [Google Scholar]
  53. Tanew A., Guggenbichler A., Hönigsmann H., Geiger J. M., Fritsch P. Photochemotherapy for severe psoriasis without or in combination with acitretin: a randomized, double-blind comparison study. J Am Acad Dermatol. 1991 Oct;25(4):682–684. doi: 10.1016/0190-9622(91)70253-x. [DOI] [PubMed] [Google Scholar]
  54. Van Seventer G. A., Shimizu Y., Horgan K. J., Luce G. E., Webb D., Shaw S. Remote T cell co-stimulation via LFA-1/ICAM-1 and CD2/LFA-3: demonstration with immobilized ligand/mAb and implication in monocyte-mediated co-stimulation. Eur J Immunol. 1991 Jul;21(7):1711–1718. doi: 10.1002/eji.1830210719. [DOI] [PubMed] [Google Scholar]
  55. Waters C. A., Snider C. E., Itoh K., Poisson L., Strom T. B., Murphy J. R., Nichols J. C. DAB486IL-2 (IL-2 toxin) selectively inactivates high-affinity IL-2 receptor-bearing human peripheral blood mononuclear cells. Ann N Y Acad Sci. 1991 Dec 30;636:403–405. doi: 10.1111/j.1749-6632.1991.tb33479.x. [DOI] [PubMed] [Google Scholar]
  56. Werther W. A., Gonzalez T. N., O'Connor S. J., McCabe S., Chan B., Hotaling T., Champe M., Fox J. A., Jardieu P. M., Berman P. W. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol. 1996 Dec 1;157(11):4986–4995. [PubMed] [Google Scholar]
  57. Yamamoto T., Matsuuchi M., Katayama I., Nishioka K. Repeated subcutaneous injection of staphylococcal enterotoxin B-stimulated lymphocytes retains epidermal thickness of psoriatic skin-graft onto severe combined immunodeficient mice. J Dermatol Sci. 1998 May;17(1):8–14. doi: 10.1016/s0923-1811(97)00064-9. [DOI] [PubMed] [Google Scholar]
  58. Yamamoto Toshiyuki, Nishioka Kiyoshi. Topical tacrolimus: an effective therapy for facial psoriasis. Eur J Dermatol. 2003 Sep-Oct;13(5):471–473. [PubMed] [Google Scholar]
  59. Zackheim H. S., Glogau R. G., Fisher D. A., Maibach H. I. 6-Thioguanine treatment of psoriasis: experience in 81 patients. J Am Acad Dermatol. 1994 Mar;30(3):452–458. doi: 10.1016/s0190-9622(94)70055-9. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES